A UK-based phase I trial of recombinant modified vaccinia ankara (MVA) vaccine encoding Epstein-Barr virus (EBV) antigens.
N. M. Steven
No relevant relationships to disclose
K. J. Harrington
No relevant relationships to disclose
L. Lee
No relevant relationships to disclose
H. Jia
No relevant relationships to disclose
M. K. Tanday
No relevant relationships to disclose
C. Roberts
No relevant relationships to disclose
C. Edwards
No relevant relationships to disclose
L. McGuigan
No relevant relationships to disclose
A. G. J. Hartley
No relevant relationships to disclose
M. Viskaduraki
No relevant relationships to disclose
E. P. Hui
No relevant relationships to disclose
A. T. C. Chan
No relevant relationships to disclose
A. B. Rickinson
No relevant relationships to disclose
G. S. Taylor
No relevant relationships to disclose